Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Medicine Center of Excellence, |
RCV003455900 | SCV004183330 | benign | Greig cephalopolysyndactyly syndrome | 2023-12-12 | criteria provided, single submitter | research | |
Fulgent Genetics, |
RCV005047590 | SCV005668775 | uncertain significance | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome; Polysyndactyly 4; Polydactyly, postaxial, type A1 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005220717 | SCV005869370 | uncertain significance | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome | 2024-09-15 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 803 of the GLI3 protein (p.Ala803Pro). This variant is present in population databases (rs779956431, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with GLI3-related conditions. Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GLI3 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |